CG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data could position it as a best-in-class therapy for high-risk non-muscle invasive bladder cancer (NMIBC) compared to a competing Phase III candidate from Johnson & Johnson, as well as Merck & Co.’s Keytruda (pembrolizumab).
Key Takeaways
- CG Oncology sees additional Phase III data for cretostimogene as bolstering its case that the oncolytic immunotherapy is a best-in-class therapy for non-muscle invasive bladder cancer.
The company presented data from the Phase III BOND-003 monotherapy trial on 5 December at the Society of Urologic Oncology...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
